CN113164425A - 用于治疗囊性纤维化的氨基酸组合物和方法 - Google Patents

用于治疗囊性纤维化的氨基酸组合物和方法 Download PDF

Info

Publication number
CN113164425A
CN113164425A CN201980077878.6A CN201980077878A CN113164425A CN 113164425 A CN113164425 A CN 113164425A CN 201980077878 A CN201980077878 A CN 201980077878A CN 113164425 A CN113164425 A CN 113164425A
Authority
CN
China
Prior art keywords
cftr
amino acids
free amino
amino acid
certain embodiments
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980077878.6A
Other languages
English (en)
Chinese (zh)
Inventor
S·维迪亚萨格
A·格罗舍
徐晓东
林珊珊
S·普拉巴卡兰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Florida Research Foundation Inc
Original Assignee
University of Florida Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Florida Research Foundation Inc filed Critical University of Florida Research Foundation Inc
Publication of CN113164425A publication Critical patent/CN113164425A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN201980077878.6A 2018-10-30 2019-10-30 用于治疗囊性纤维化的氨基酸组合物和方法 Pending CN113164425A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862752847P 2018-10-30 2018-10-30
US62/752,847 2018-10-30
PCT/US2019/058954 WO2020092639A1 (en) 2018-10-30 2019-10-30 Amino acid compositions and methods for treating cystic fibrosis

Publications (1)

Publication Number Publication Date
CN113164425A true CN113164425A (zh) 2021-07-23

Family

ID=70464502

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980077878.6A Pending CN113164425A (zh) 2018-10-30 2019-10-30 用于治疗囊性纤维化的氨基酸组合物和方法

Country Status (10)

Country Link
US (1) US12220400B2 (https=)
EP (1) EP3873453A4 (https=)
JP (2) JP7689492B2 (https=)
KR (1) KR20210086660A (https=)
CN (1) CN113164425A (https=)
AU (2) AU2019370363B2 (https=)
BR (1) BR112021008395A2 (https=)
CA (1) CA3116015A1 (https=)
MX (1) MX2021005113A (https=)
WO (1) WO2020092639A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3177780A1 (en) * 2020-05-29 2021-12-02 University Of Florida Research Foundation, Inc. Formulations and methods for treating acute respiratory distress syndrome, asthma, or allergic rhinitis
US11878073B1 (en) 2022-09-20 2024-01-23 Entrinsic, LLC Generation of hydration-targeted formulations and methods of use therein

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040192756A1 (en) * 2001-08-08 2004-09-30 Franco Conti Amino-acid-based compositions, suitable in therapy for the healing and/or mending of wounds and lesions, in particular for application in the opthalmic field
WO2004110383A2 (en) * 2003-06-11 2004-12-23 Matthias Rath Pharmaceutical composition and method for alleviating side effects of estrogen replacement therapy
CN1671734A (zh) * 2002-05-31 2005-09-21 儿童医院医疗中心 用于治疗囊性纤维化的cftr修饰基因和表达的多肽以及检测和/或鉴定它们的方法和产品
CN1761472A (zh) * 2003-03-21 2006-04-19 皇家亚力山大儿童医院 细胞表面蛋白质的调节
CN1838964A (zh) * 2002-04-25 2006-09-27 斯克里普斯研究学院 肺病的治疗与预防
CN107205994A (zh) * 2014-11-26 2017-09-26 克塔巴西斯制药有限公司 脂肪酸半胱胺缀合物和它们作为自噬的活化剂的用途
CN108463223A (zh) * 2015-10-09 2018-08-28 艾伯维公司 用于治疗囊性纤维化的增效剂-校正剂组合

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030224071A1 (en) * 1999-08-20 2003-12-04 Howard Murad Pharmaceutical compositions and methods for managing connective tissue ailments
WO2002098405A1 (fr) 2001-06-05 2002-12-12 Ajinomoto Co., Inc. Inhibiteurs de fibrose du foie
WO2003055481A1 (en) 2001-12-25 2003-07-10 Ajinomoto Co., Inc. Organ fibrosis inhibitors
US8389736B2 (en) 2007-10-16 2013-03-05 The Regents Of The University Of California Compounds having activity in correcting mutant-CFTR processing and uses thereof
ITTO20080443A1 (it) 2008-06-06 2009-12-07 Professional Dietetics Srl Composizioni comprendenti amminoacidi, con attivita' pro-angiogenica
EP2664326B1 (en) 2012-05-17 2017-11-01 I.E.R.F.C. European Institute for Cystic Fibrosis Research Combined therapy for cystic fibrosis
US20140221424A1 (en) 2013-01-30 2014-08-07 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions for use in the treatment of cystic fibrosis
WO2016191263A1 (en) 2015-05-22 2016-12-01 Trustees Of Dartmouth College Therapy and kit for the prevention and treatment of cystic fibrosis
MA45397A (fr) * 2016-06-21 2019-04-24 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040192756A1 (en) * 2001-08-08 2004-09-30 Franco Conti Amino-acid-based compositions, suitable in therapy for the healing and/or mending of wounds and lesions, in particular for application in the opthalmic field
CN1838964A (zh) * 2002-04-25 2006-09-27 斯克里普斯研究学院 肺病的治疗与预防
CN1671734A (zh) * 2002-05-31 2005-09-21 儿童医院医疗中心 用于治疗囊性纤维化的cftr修饰基因和表达的多肽以及检测和/或鉴定它们的方法和产品
CN1761472A (zh) * 2003-03-21 2006-04-19 皇家亚力山大儿童医院 细胞表面蛋白质的调节
WO2004110383A2 (en) * 2003-06-11 2004-12-23 Matthias Rath Pharmaceutical composition and method for alleviating side effects of estrogen replacement therapy
CN107205994A (zh) * 2014-11-26 2017-09-26 克塔巴西斯制药有限公司 脂肪酸半胱胺缀合物和它们作为自噬的活化剂的用途
CN108463223A (zh) * 2015-10-09 2018-08-28 艾伯维公司 用于治疗囊性纤维化的增效剂-校正剂组合

Also Published As

Publication number Publication date
AU2019370363A1 (en) 2021-05-13
JP2022506044A (ja) 2022-01-17
KR20210086660A (ko) 2021-07-08
AU2025248660A1 (en) 2025-10-30
BR112021008395A2 (pt) 2021-09-28
EP3873453A4 (en) 2022-08-03
US12220400B2 (en) 2025-02-11
JP7689492B2 (ja) 2025-06-06
JP2025128185A (ja) 2025-09-02
CA3116015A1 (en) 2020-05-07
MX2021005113A (es) 2021-06-15
US20210393584A1 (en) 2021-12-23
AU2019370363B2 (en) 2025-07-10
WO2020092639A1 (en) 2020-05-07
EP3873453A1 (en) 2021-09-08

Similar Documents

Publication Publication Date Title
Rotin et al. Function and regulation of the epithelial Na+ channel ENaC
Wang et al. The heme oxygenase-1/carbon monoxide pathway suppresses TLR4 signaling by regulating the interaction of TLR4 with caveolin-1
JP2025128185A (ja) 喘息またはｃｏｐｄを治療するためのアミノ酸組成物及び方法
Valério et al. New insights on the mode of action of microcystins in animal cells-a review
Czikora et al. A novel tumor necrosis factor–mediated mechanism of direct epithelial sodium channel activation
TWI870336B (zh) 重組人類酸性α-葡萄糖苷酶
WO2009003147A1 (en) Methods and compositions for the treatment of neurological disorders
JP7482914B2 (ja) ホモシスチン尿症の治療する組成物および方法
Leier et al. Sildenafil acts as potentiator and corrector of CFTR but might be not suitable for the treatment of CF lung disease
AU2025201099A1 (en) Compositions and methods for delivering CFTR polypeptides
WO2019070759A1 (en) AMINO ACID COMPOSITIONS AND METHODS FOR TREATING CYSTIC FIBROSIS
US20220218678A1 (en) Use of 1-phenyl-2-pyridinyl alkyl alcohol derivatives for treating cystic fibrosis
JP7630540B2 (ja) 神経保護ペプチド
Tomich et al. Channel replacement therapy for cystic fibrosis
WO2017147420A1 (en) Methods and compositions with vitamin d compounds for treatment of cystic fibrosis and respiratory disorders
Handjieva-Darlenska et al. Emerging pharmacotherapies to fight obesity and related disorders.
Hildebrandt et al. Characterization of chronic nicotine exposure on the survival of the" spastic" Han-Wistar rat
KR20250114044A (ko) 만성 호흡기 질환 치료약
WO2026090584A2 (en) Methods of treating peripheral nervous system myelination conditions
Sharma Novel Approaches To Enhance Translational Readthrough Efficacy For Cystic Fibrosis Nonsense Mutations
EP4314010A1 (en) Modified peptidomimetics and methods of use
Layman Studies on the effect of tryptophan substitutions in channel-forming peptide: CK4M2GLYR

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination